Daniel Lorrain
Fondateur chez CONTINEUM THERAPEUTICS, INC.
Fortune : 3 M $ au 31/05/2024
Profil
Daniel S.
Lorrain is the founder and the Chief Science Officer at Contineum Therapeutics, Inc., a company founded in 2017.
He held the position of Senior Director at Amira Pharmaceuticals, Inc. from 2005 to 2010.
From 2011 to 2018, he served as the Vice President-Biology at Inception Sciences, Inc. Dr. Lorrain obtained his undergraduate and doctorate degrees from the State University of New York at Buffalo.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 24/05/2024 | 179 335 ( 0,94% ) | 3 M $ | 31/05/2024 |
Postes actifs de Daniel Lorrain
| Sociétés | Poste | Début |
|---|---|---|
| CONTINEUM THERAPEUTICS, INC. | Fondateur | 09/05/2017 |
Anciens postes connus de Daniel Lorrain
| Sociétés | Poste | Fin |
|---|---|---|
Inception Sciences, Inc.
 Inception Sciences, Inc. Pharmaceuticals: MajorHealth Technology Inception Sciences, Inc. provides small molecule pharmaceutical incubator services. Its focus is on creating therapies with transformative potential to address diseases and disorders. The company creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded in 2011 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 10/01/2018 |
Amira Pharmaceuticals, Inc.
 Amira Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. The firm's team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. | Directeur/Membre du Conseil | 01/01/2010 |
Formation de Daniel Lorrain
| State University of New York at Buffalo | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CONTINEUM THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Inception Sciences, Inc.
Inception Sciences, Inc. Pharmaceuticals: MajorHealth Technology Inception Sciences, Inc. provides small molecule pharmaceutical incubator services. Its focus is on creating therapies with transformative potential to address diseases and disorders. The company creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded in 2011 and is headquartered in San Diego, CA. | Health Technology |
Amira Pharmaceuticals, Inc.
Amira Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. The firm's team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. | Health Technology |
